Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato2.1B+ 100.0%
<1.7B <1%
1.7B–1.8B <1%
1.8B–1.9B <1%
$27,755 Vol.
$27,755 Vol.
17 apr 2026
<1.7B
No
1.7B–1.8B
No
1.8B–1.9B
No
1.9B–2.0B
No
2.0B–2.1B
No
2.1B+
Yes
No IPO before June 2026
No
2.1B+ 100.0%
<1.7B <1%
1.7B–1.8B <1%
1.8B–1.9B <1%
$27,755 Vol.
$27,755 Vol.
17 apr 2026
<1.7B
$1,472 Vol.
No
1.7B–1.8B
$3,525 Vol.
No
1.8B–1.9B
$2,327 Vol.
No
1.9B–2.0B
$2,681 Vol.
No
2.0B–2.1B
$3,265 Vol.
No
2.1B+
$13,975 Vol.
Yes
No IPO before June 2026
$510 Vol.
No
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercato aperto: Apr 14, 2026, 5:05 PM ET
Volume
$27,755Data di fine
17 apr 2026Mercato aperto
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...Esito proposto: No
Nessuna contestazione
Esito finale: No
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$27,755Data di fine
17 apr 2026Mercato aperto
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...Esito proposto: No
Nessuna contestazione
Esito finale: No
Kailera Therapeutics' IPO debut on April 17 drove overwhelming trader consensus for a closing market cap exceeding $2.1 billion, as shares surged 62.5% from $16 pricing to close around $26, boosting fully diluted market cap to approximately $3.1 billion on elevated trading volume. This record $625 million raise—the largest biotech IPO in years—reflects surging demand for obesity treatments, anchored by Kailera's late-stage GLP-1 assets licensed from Hengrui Pharma and led by experienced CEO Ron Renaud. Polymarket's 100% implied probability captures skin-in-the-game sentiment amid biotech IPO revival, with the offering set to close April 20. Realistic challenges are slim, requiring a sharp reversal from unforeseen dilution or market-wide selloff before resolution.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti